How existing technologies and approaches such as targeted AI deployment can help make prior authorization workflows more ...
In the first part of her interview with Pharmaceutical Executive, Sandra Coufal, MD, CEO of Toragen, explains why the HPV E5 ...
In today's Pharmaceutical Executive Daily, the FDA grants accelerated approval to BeOne Medicines' Beqalzi as the first and only BCL2 inhibitor for relapsed or refractory mantle cell lymphoma, while ...
Accelerated approval of sonrotoclax establishes a targeted BCL2 option in post–BTK inhibitor relapsed/refractory mantle cell lymphoma, a setting with limited effective salvage therapies and poor ...
The World Health Assembly's new resolution on transparency in the market for health-related products is weaker than the original draft but still contains measures that could have a substantial impact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results